Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22686378 | 1.00 | ALDH1A1 (0.42) | ALDH1A1LMNACHRNA7TDP1CHRNB2 | |
| Formaldoxime SCHEMBL28447516 | 0.92 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL21647191 | 0.84 | CHRNB2 (0.47) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6366698 | 0.80 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL28961390 | 0.73 | CHRNB2 (0.55) | ALDH1A1LMNACHRNA7TDP1CHRNB2 | |
| SCHEMBL4299439 | 0.72 | NTRK1 (0.47) | — | |
| SCHEMBL11233101 | 0.72 | CHRNB2 (0.43) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3058805 | 0.71 | CHRNB2 (0.62) | ALDH1A1LMNACHRNA7TDP1CHRNB2 | |
| SCHEMBL3058809 | 0.71 | CHRNB2 (0.62) | ALDH1A1LMNACHRNA7TDP1CHRNB2 | |
| SCHEMBL17264284 | 0.71 | CHRNB2 (0.62) | ALDH1A1LMNACHRNA7TDP1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| CN-111620865-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3753943-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-26 | — | — | US | disclosed |
| CN-111620864-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111620865-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-110156772-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | ENPP2, ATXN10, PCSK9 | ALDH1A1 3517/4885LMNA 1935/4885CHRNA7 859/4885 |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ENPP2, ATXN10, PCSK9 | ALDH1A1 3517/4885LMNA 1935/4885CHRNA7 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.